Concluding Remarks

[1] Belien P(2000)Healthcare systems: a new European model? Pharmacoeconomics 18 85-93

[2] Prewo W(2000)Consumer empowerment as a solution to health system financing Pharmacoeconomics 18 77-83

[3] Herzlinger R(2000)US economic revolution: mapping the future of healthcare Pharmacoeconomics 18 3-6

[4] van der Zeijden A(2000)The patient rights movement in Europe Pharmacoeconomics 18 7-13

[5] Sommer A(2000)Restructuring French hospitals: some problems and some solutions Pharmacoeconomics 18 69-76

[6] Miller RD(2000)Is there a link between pharmaceutical consumption and improved health in OECD countries? Pharmacoeconomics 18 33-45

[7] Frech HE(2000)Payment systems and considerations of case mix - are diagnosis-related groups applicable in Japan? Pharmacoeconomics 18 95-110

[8] Kawabuchi K(2000)Post-modern drug evaluation: the deconstruction of evidence-based regulation Pharmacoeconomics 18 15-20

[9] Avorn J(2000)The distribution of sales revenues from pharmaceutical innovation Pharmacoeconomics 18 21-32

[10] Grabowski HG(2000)Reimbursement for new health technologies: breakthrough pharmaceuticals as a 20th century challenge Pharmacoeconomics 18 59-67

[1] Belien P(2000)Healthcare systems: a new European model? Pharmacoeconomics 18 85-93

[2] Prewo W(2000)Consumer empowerment as a solution to health system financing Pharmacoeconomics 18 77-83

[3] Herzlinger R(2000)US economic revolution: mapping the future of healthcare Pharmacoeconomics 18 3-6

[4] van der Zeijden A(2000)The patient rights movement in Europe Pharmacoeconomics 18 7-13

[5] Sommer A(2000)Restructuring French hospitals: some problems and some solutions Pharmacoeconomics 18 69-76

[6] Miller RD(2000)Is there a link between pharmaceutical consumption and improved health in OECD countries? Pharmacoeconomics 18 33-45

[7] Frech HE(2000)Payment systems and considerations of case mix - are diagnosis-related groups applicable in Japan? Pharmacoeconomics 18 95-110

[8] Kawabuchi K(2000)Post-modern drug evaluation: the deconstruction of evidence-based regulation Pharmacoeconomics 18 15-20

[9] Avorn J(2000)The distribution of sales revenues from pharmaceutical innovation Pharmacoeconomics 18 21-32

[10] Grabowski HG(2000)Reimbursement for new health technologies: breakthrough pharmaceuticals as a 20th century challenge Pharmacoeconomics 18 59-67